Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > The Brazil contract is actually around $150 million for LABS
View:
Post by subaru1i on Oct 05, 2023 2:08pm

The Brazil contract is actually around $150 million for LABS

to become profitable in Q1 2024 based on their gross profit margins.  That's just for one quarter, so how big then is the total contract minimum on an annualized basis.  

Big news on the way folks, hope others are feathering their nest.
Comment by Starkicker on Oct 05, 2023 2:15pm
I think I liked it better two or three years ago when you used to just say BIG NEWS COMING because then I didn't have to go and fact check your math. These more elaborate speculations are time consuming...lol.
Comment by subaru1i on Oct 05, 2023 2:18pm
Starkicker, my historical comment still holds true to this day and I have invited Icfa to validate my logic so as not to impinge on your time.   But this is not elaborate at all...it is in fact a method used by companies for financial planning and making their cash forecasts for the year.   
Comment by Starkicker on Oct 05, 2023 2:46pm
True,  but you don't have all of the information and variables, including if the Brazil partnership is indeed the revenue generator. A lot of quantum leaps and assumptions in your speculation. Don't get me wrong, I hope you're right, but I strongly doubt Mr. Pidduck is intentionally leaving bread crumbs for us. 
Comment by mdjbrown on Oct 05, 2023 3:04pm
Here is what we know so far with regards to Brazil and Medipharm -   In 2020 Medipharm partnered up with XLR8 and one could assume that represents any current reported revenue from Brazil. “As early participants in the Brazilian medical cannabis industry dating back to its involvement in the pioneering import of medical cannabis oil for patient use from Canada to Brazil in 2017, XLR8 is ...more  
Comment by subaru1i on Oct 05, 2023 3:12pm
Okay, lets normalize out of the equation Brazil as the revenue generator.  Q1 2024 profitability is Mr. Pidduck's quantum leaps and assumptions and I'm only working from that along with the given financial data.   We still need a contract of approximately $150 million for Q1 at approx 21% gross margins to generate a penny per share in earnings.  Pidduck is leaving ...more  
Comment by TreborTheGreat on Oct 05, 2023 3:45pm
This is gaslighting.  Medpharm does not have a $150MM Brazil contract. This is you swagging "potential" again. Yes, lot of potential.  So what?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities